Evidence map›Paper›PMID 40523941›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Assessing the frequency and accuracy of morphologic changes of focal bone lesions on [

Thibika Sivakumar, Jakob Heimer, Stephan Beintner-Skawran, Urs J Muehlematter, Michael Messerli, Noel Spielhofer, Daniel Eberli, Martin W Huellner, Irene A Burger, Alexander Maurer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Thibika SivakumarDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4228-1950
Jakob HeimerDepartment of Nuclear Medicine, Affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, Switzerland.ORCID 0000-0003-3499-8801
Stephan Beintner-SkawranDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-2721-9726
Urs J MuehlematterDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-3423-4633
Michael MesserliDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7815-3048
Noel SpielhoferDepartment of Nuclear Medicine, Affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, Switzerland.ORCID 0009-0005-5690-6375
Daniel EberliDepartment of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-8866-8010
Martin W HuellnerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4849-3292
Irene A BurgerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-8029-8692
Alexander MaurerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland. alexander.maurer@usz.ch.ORCID 0000-0002-6964-802X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn [

methodsThis single-center, retrospective study included patients who underwent a [

resultsOut of 824 patients, 323 met eligibility criteria, with 101 showing PSMA-positive bone lesions. 176 lesions were included, 25% of 61 in the staging cohort had no MC, of which 73% were malignant. In the BCR group, 52% of 115 lesions were without MC, of which 48% were malignant. The sensitivity/specificity reached with PSMA-RADS 2.0, and MC on CT was 100%/100%and 78%/36% for staging, and 83%/100% and 60%/72% for BCR, respectively.

conclusionFocal [

Indexed as

Bone NeoplasmsEdetic AcidOligopeptidesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedRetrospective StudiesEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesPSMA-11Computer tomographyMorphological correlatePSMA-RADSSclerosisUnspecific bone uptake

Identifiers

PMID40523941
PMCPMC12660395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.